Shuai Y, Yang G, Zhang Q, Li W, et al. Efficacy and safety of polyethylene glycol loxenatide (PEX168) monotherapy in type 2 diabetes patients: a multicenter, randomized, double-blind, placebo-controlled, phase 3a clinical trial. Diabetes Obes Metab 2020 Sep 23. doi: 10.1111/dom.14198.
PMID: 32965075